

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Guidance development

MT273 PneuX to prevent ventilator-associated pneumonia

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified during scoping. Risk factors for VAP include age (incidence increases with advancing age) and chronic illnesses (including underlying chronic lung disease, cancer and diabetes), which may significantly affect activities of daily living to the point where a person can be considered to be disabled. Age and disability are protected characteristics under the Equality Act (2010).

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No equality issues were identified.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No equality issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

Not applicable

Approved by Associate Director: Joanne Holden

Date: 6 November 2019

Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

N/A

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

N/A

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

Not applicable

Approved by Programme Director: Joanne Holden

Date: 28 January 2019